NCT05386355

Brief Summary

This study will determine the effectiveness of a vaccine communication mobile health app on parental decisions to vaccinate their children against coronavirus disease 2019 (COVID-19). The hypothesis is that unvaccinated children of caregivers assigned to the Vaccine Uptake app will be more likely to achieve COVID-19 vaccine series completion than those children whose caregivers are assigned to the General Health app.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,934

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Jul 2022

Geographic Reach
1 country

15 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 19, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

May 23, 2022

Completed
2 months until next milestone

Study Start

First participant enrolled

July 18, 2022

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 25, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 25, 2023

Completed
1.5 years until next milestone

Results Posted

Study results publicly available

March 11, 2025

Completed
Last Updated

March 11, 2025

Status Verified

February 1, 2025

Enrollment Period

1.2 years

First QC Date

May 19, 2022

Results QC Date

September 26, 2024

Last Update Submit

February 19, 2025

Conditions

Keywords

COVID-19COVID-19 vaccinationPediatric COVID-19 vaccinationmobile healthmHealth

Outcome Measures

Primary Outcomes (1)

  • Proportion of Children Who Complete COVID-19 Vaccination, as Verified in State, Clinic, or Participant-held Records

    Initiation and completion of the COVID-19 vaccine series during the 24-week intervention period. Vaccine series completion will be per ACIP guidance for the vaccine product. For children who receive a product that requires more than 2 doses for the primary series, receipt of up to 3 doses will be considered complete. Vaccine doses will be valid if given within 24-week study intervention. Additional doses for primary series completion will be valid if they are in accordance with ACIP-recommended interval minus a 4-day grace period. There will be no maximum interval between valid doses. An incorrect second vaccine product (i.e., mixed series) will be invalid. The statistical team will use a mixed model with the binomial distribution and the logit link to compare the two intervention groups and the proportions of children who complete COVID-19 vaccination, using a site random effect and controlling for clustering by caregiver.

    Week 24

Secondary Outcomes (2)

  • Proportion of Children Who Receive ≥1 Dose of the COVID-19 Vaccination Series, as Verified in State, Clinic, or Participant-held Records

    Week 24

  • Change in Enrolled Parent/Caregiver Domain Scores From Baseline to Immediately Post-intervention on the Modified WHO SAGE Vaccine Hesitancy Scale Adapted for the COVID-19 Vaccine

    16 weeks

Study Arms (2)

Vaccine Uptake App

EXPERIMENTAL

24-week (8 weeks with weekly push notifications; 2 monthly push notifications for 2 months \[1 notification per month\]; 8 weeks without) exposure to a mobile phone application (app) designed to improve parental knowledge, attitudes, and self-efficacy regarding pediatric COVID-19 vaccination. The app will address logistical and motivational barriers to pediatric COVID-19 vaccination. Participants will also receive eight weekly nudges and 1 monthly nudge for 2 months (cues to action) regarding vaccinating their child that will be sent to participants via push notifications to their mobile devices. Through branching logic, users will access content tailored to their COVID-19 vaccine knowledge and confidence gaps, locality, degree of rural-urban primary residence, primary language (English/Spanish), race/ethnicity, and child's age.

Behavioral: COVID-19 Vaccine Uptake App

General Health App

ACTIVE COMPARATOR

24-week (8 with weekly push notifications; 2 monthly push notifications for 2 months \[1 notification per month\]; 8 weeks without) exposure to a mobile phone app designed to provide information on general pediatric health and infection prevention and mitigation strategies based on recommendations from the American Academy of Pediatrics (AAP) and the Centers for Disease Control and Prevention (CDC). Eight weekly nudges and 1 monthly nudge for 2 months regarding these topics will be sent to participants via push notifications to their mobile devices.

Other: General Health App

Interventions

A mHealth mobile application (app) that will provide educational and logistical information about the COVID-19 vaccination for children. The target audience will be parents of unvaccinated children.

Vaccine Uptake App

A mobile application (app) that will provide general pediatric health and infection prevention and mitigation strategies.

General Health App

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Age of majority, as defined by the state of residency
  • Access to a mobile device that can store and run the study app for 24 weeks. Devices that can run the app include mobile phones and tablets running Android or iOS operating systems
  • Able to speak and read in English or Spanish
  • Age 6 months to less than age of majority, as defined by the child's state of residence
  • Has not received any doses of COVID-19 vaccine based on parent/caregiver report
  • Eligible to receive COVID-19 vaccine
  • Patient at a participating clinic

You may not qualify if:

  • Has only a child or children with known contraindication to all COVID-19 vaccines
  • Has only a child or children whose other parent/caregiver is already a current or past participant in the study
  • Has a child or children enrolled in any other COVID-19 vaccine study of any kind
  • Past or present participation in a COVID-19 vaccine or behavioral trial
  • Has a cognitive impairment that limits their ability to engage with the app content and/or make medical decisions regarding vaccination, based on the site investigator's assessment and local human subjects research policies
  • Not a patient of a participating clinic
  • Prior receipt of least one dose of COVID-19 vaccine
  • Receiving or scheduled to receive COVID-19 vaccination at the time of parental consent
  • Known medical contraindication to all COVID-19 vaccines
  • Ineligible to receive COVID-19 vaccine
  • Prior or current participation in a COVID-19 vaccine study of any kind

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (15)

Arkansas Children's Research Institute

Little Rock, Arkansas, 72202, United States

Location

Nemours Children's Health

Wilmington, Delaware, 19803, United States

Location

Kapiolani Medical Center for Women and Children

Honolulu, Hawaii, 96813, United States

Location

University of Kansas Medical Center

Kansas City, Kansas, 66160, United States

Location

Norton Children's Research Institute

Louisville, Kentucky, 40202, United States

Location

Our Lady of the Lake Regional Medical Center

Baton Rouge, Louisiana, 70808, United States

Location

University of Mississippi Medical Center

Jackson, Mississippi, 39216, United States

Location

University of Nebraska Medical Center

Omaha, Nebraska, 68198, United States

Location

Dartmouth Hitchcock Clinic

Lebanon, New Hampshire, 03756, United States

Location

University of New Mexico Health Sciences Center

Albuquerque, New Mexico, 87102, United States

Location

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104, United States

Location

Rhode Island Hospital

Providence, Rhode Island, 02903, United States

Location

Medical University of South Carolina

Charleston, South Carolina, 29425, United States

Location

Avera Research Institute

Sioux Falls, South Dakota, 57108, United States

Location

West Virginia University

Morgantown, West Virginia, 26506, United States

Location

Related Publications (2)

  • McCulloh RJ, Darden PM, Snowden J, Ounpraseuth S, Lee J, Clarke M, Newcomer SR, Fu L, Hubberd D, Baldner J, Garza M, Kerns E. Improving pediatric COVID-19 vaccine uptake using an mHealth tool (MoVeUp): study protocol for a randomized, controlled trial. Trials. 2022 Oct 28;23(1):911. doi: 10.1186/s13063-022-06819-3.

  • McCulloh RJ, Darden P, Snowden J, Ounpraseuth S, Lee J, Clarke M, Newcomer SR, Fu L, Hubberd D, Baldner J, Garza M, Kerns E. Improving pediatric COVID-19 vaccine uptake using an mHealth tool (MoVeUP): a randomized, controlled trial. Res Sq [Preprint]. 2022 Oct 10:rs.3.rs-2070396. doi: 10.21203/rs.3.rs-2070396/v1.

MeSH Terms

Conditions

Vaccination HesitancyPrecursor Cell Lymphoblastic Leukemia-LymphomaCOVID-19

Condition Hierarchy (Ancestors)

Vaccination RefusalTreatment RefusalTreatment Adherence and ComplianceHealth BehaviorBehaviorLeukemia, LymphoidLeukemiaNeoplasms by Histologic TypeNeoplasmsHematologic DiseasesHemic and Lymphatic DiseasesLymphoproliferative DisordersLymphatic DiseasesImmunoproliferative DisordersImmune System DiseasesPneumonia, ViralPneumoniaRespiratory Tract InfectionsInfectionsVirus DiseasesCoronavirus InfectionsCoronaviridae InfectionsNidovirales InfectionsRNA Virus InfectionsLung DiseasesRespiratory Tract Diseases

Results Point of Contact

Title
Songthip Ounpraseuth
Organization
University of Arkansas for Medical Sciences

Study Officials

  • Russell J. McCulloh, MD

    University of Nebraska

    PRINCIPAL INVESTIGATOR
  • Ellen Kerns, PhD

    University of Nebraska

    PRINCIPAL INVESTIGATOR
  • Paul Darden, MD

    University of Arkansas

    PRINCIPAL INVESTIGATOR
  • Songthip T Ounpraseuth, PhD

    University of Arkansas

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
OTHER
Intervention Model
PARALLEL
Model Details: The study will use a 1:1 parallel design at the caregiver level to assign caregivers to the intervention (Vaccine Uptake app) or the control (General Health app) arm. The study team will stratify randomization by participating clinic and in varying block of participants using a permuted design. Randomization will occur after enrollment and before the baseline assessment.
Sponsor Type
NETWORK
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 19, 2022

First Posted

May 23, 2022

Study Start

July 18, 2022

Primary Completion

September 25, 2023

Study Completion

September 25, 2023

Last Updated

March 11, 2025

Results First Posted

March 11, 2025

Record last verified: 2025-02

Data Sharing

IPD Sharing
Will share

We will conduct this trial in accordance with the following publication and data sharing policies and regulations: * NIH Public Access Policy. It requires scientists to submit final peer-reviewed journal manuscripts that arise from NIH funds to the digital archive PubMed Central upon acceptance for publication. * ECHO ISPCTN Publications and Presentations Policy. It ensures accurate, responsible, and efficient communication of findings from ECHO ISPCTN clinical trials. * NIH Data Sharing Policy and the policy on the Dissemination of NIH-Funded Clinical Trial Information and the Clinical Trials Registration and Resulting Information Submission Rule. Other researchers may request data from this trial by contacting Jeannette Lee, Ph.D., at the ISPCTN Data Coordinating and Operations Center (DCOC).

Shared Documents
SAP, ICF
Time Frame
Per data sharing polices of NIH and the ISPCTN
Access Criteria
to be announced

Locations